Repatha (evolocumab) is an injectable medication used to lower LDL cholesterol in people whose levels remain too high despite diet changes and maximum statin therapy. It is FDA-approved for adults with established cardiovascular disease, adults and children (age 10 and older) with inherited high cholesterol conditions, and adults with primary hyperlipidemia who need additional LDL reduction. Beyond lowering cholesterol numbers, Repatha has been shown to reduce the risk of heart attacks and strokes in high-risk patients.
The Three Main Uses
Repatha is approved for three overlapping but distinct patient groups. The first and most common is adults who already have atherosclerotic cardiovascular disease, meaning they’ve had a heart attack, stroke, or have significant plaque buildup in their arteries. For these patients, Repatha is added on top of the highest statin dose they can tolerate when their LDL cholesterol still isn’t low enough.
The second group includes people with heterozygous familial hypercholesterolemia (HeFH), a genetic condition where one copy of a faulty gene causes persistently high cholesterol from a young age. About 1 in 250 people carry this mutation. Repatha is approved for both adults and children aged 10 and older with HeFH.
The third group is people with homozygous familial hypercholesterolemia (HoFH), a rarer and more severe form where both copies of the gene are affected. Untreated LDL levels in these patients can exceed 500 mg/dL. Repatha is used alongside other cholesterol-lowering treatments, including statins and sometimes a procedure called LDL apheresis that physically filters cholesterol from the blood. Clinical guidelines now recommend trying Repatha in HoFH patients regardless of how much residual LDL receptor function they have.
How Repatha Lowers Cholesterol
Your liver clears LDL cholesterol from the bloodstream using surface receptors that grab LDL particles and pull them in for disposal. A protein called PCSK9 normally breaks down these receptors after each use, limiting how many are available at any given time. Repatha is a monoclonal antibody, a lab-engineered protein that binds to PCSK9 and blocks it from doing its job. With PCSK9 out of the way, more LDL receptors survive and recycle back to the liver’s surface, pulling significantly more cholesterol out of circulation.
This mechanism also appears to reduce levels of lipoprotein(a), a particularly stubborn type of cholesterol-carrying particle linked to heart disease that statins barely touch. In clinical trials, Repatha reduced lipoprotein(a) by roughly 20% to 38%, depending on the dosing schedule. Researchers believe the increased number of LDL receptors allows the liver to capture lipoprotein(a) particles that would otherwise compete poorly for receptor binding.
How Much It Lowers LDL
The cholesterol reductions with Repatha are substantial. In pooled data from multiple clinical trials, patients on the every-two-week dose saw their non-HDL cholesterol drop by 49% to 56%, while those on the monthly dose saw reductions of 48% to 52%. Apolipoprotein B, a protein that serves as a marker for the total number of harmful cholesterol particles in your blood, dropped by 40% to 52%.
These reductions are on top of whatever benefit patients were already getting from statins. Current American Heart Association and American College of Cardiology guidelines recommend adding a drug like Repatha when a patient on maximum statin therapy still has an LDL level at or above 70 mg/dL. For very high-risk patients, intensifying therapy may be reasonable even at levels between 55 and 70 mg/dL.
Heart Attack and Stroke Prevention
Lowering cholesterol is the immediate goal, but the real question is whether that translates to fewer cardiovascular events. The FOURIER trial, which enrolled 12,257 high-risk patients, found that adding Repatha to standard statin therapy reduced the combined risk of a first heart attack, first stroke, or death from coronary heart disease by 25%. The reduction in heart attacks specifically was 36% compared to placebo.
The benefit grew over time. During the first year of the trial, each significant drop in LDL cholesterol was associated with a 10% reduction in major vascular events. By the second year, that figure rose to 17%. This pattern suggests that the longer harmful cholesterol levels stay low, the more the arteries benefit.
How Repatha Is Taken
Repatha is a self-administered injection given under the skin of the abdomen, thigh, or upper arm. You rotate injection sites each time. There are two standard dosing options: 140 mg every two weeks, or 420 mg once a month. Both schedules produce comparable cholesterol reductions, so the choice comes down to preference and convenience.
For patients with HoFH, treatment starts at 420 mg once monthly. If cholesterol hasn’t dropped enough after 12 weeks, the frequency can be increased to every two weeks. Patients who are also receiving LDL apheresis typically start at the every-two-week schedule to align with their apheresis sessions, with the injection given after each session is complete.
Response in HoFH Patients
Repatha works best when LDL receptors are at least partially functional, which is why results in HoFH patients are more variable than in other groups. In pooled data from three studies of pediatric HoFH patients aged 10 to 17, about 43% of those not on apheresis achieved at least a 15% LDL reduction at 12 weeks. The median reduction was modest at around 3%, but individual responses varied widely, with some patients seeing drops exceeding 20%. That variability is why guidelines recommend a trial period: even if the average response is smaller than in other populations, a meaningful portion of HoFH patients do benefit enough to justify continuing treatment.
Who Typically Gets Prescribed Repatha
Repatha is not a first-line cholesterol drug. It fills a specific gap for people whose LDL remains dangerously high despite doing everything else right. The typical patient has already been on the highest statin dose they can handle, often with ezetimibe added, and still can’t reach their cholesterol target. This includes people recovering from heart attacks or strokes, those with progressive atherosclerotic disease, and people with genetic cholesterol disorders that don’t respond adequately to oral medications alone.
Cost has historically been a barrier. Repatha is a biologic medication, considerably more expensive than statins. Insurance coverage often requires documentation showing that other therapies have failed or are insufficient before approval. Many patients go through a prior authorization process, and the manufacturer offers savings programs for eligible patients to offset out-of-pocket costs.